AbbVie Inc (NYSE:ABBV) Shares Sold by NTV Asset Management LLC

NTV Asset Management LLC lowered its holdings in AbbVie Inc (NYSE:ABBV) by 16.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 27,770 shares of the company’s stock after selling 5,342 shares during the quarter. NTV Asset Management LLC’s holdings in AbbVie were worth $2,468,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Formidable Asset Management LLC boosted its position in shares of AbbVie by 0.3% during the second quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock worth $285,000 after buying an additional 10 shares during the period. WealthTrust Axiom LLC boosted its position in shares of AbbVie by 0.3% during the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock worth $312,000 after buying an additional 15 shares during the period. Abner Herrman & Brock LLC boosted its position in shares of AbbVie by 0.3% during the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock worth $456,000 after buying an additional 18 shares during the period. St. Louis Trust Co boosted its position in shares of AbbVie by 0.7% during the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock worth $248,000 after buying an additional 23 shares during the period. Finally, TRUE Private Wealth Advisors boosted its position in shares of AbbVie by 0.6% during the second quarter. TRUE Private Wealth Advisors now owns 4,814 shares of the company’s stock worth $349,000 after buying an additional 27 shares during the period. 69.33% of the stock is currently owned by institutional investors.

In other AbbVie news, Chairman Richard A. Gonzalez sold 218,193 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the completion of the sale, the chairman now directly owns 492,030 shares of the company’s stock, valued at approximately $46,255,740.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Timothy J. Richmond sold 87,040 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $98.45, for a total value of $8,569,088.00. Following the sale, the senior vice president now directly owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders sold a total of 450,743 shares of company stock valued at $43,153,684 over the last ninety days. 0.23% of the stock is currently owned by corporate insiders.

Several research analysts recently commented on ABBV shares. Zacks Investment Research cut AbbVie from a “buy” rating to a “hold” rating in a research report on Friday, October 20th. BidaskClub cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 25th. Piper Jaffray Companies raised their price objective on AbbVie to $115.00 and gave the company an “overweight” rating in a research report on Friday, October 27th. BMO Capital Markets set a $66.00 target price on AbbVie and gave the stock a “hold” rating in a research note on Friday, October 27th. Finally, Leerink Swann lowered their target price on AbbVie from $108.00 to $107.00 and set an “outperform” rating on the stock in a research note on Monday, October 30th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $117.26.

AbbVie Inc (NYSE ABBV) opened at $113.08 on Thursday. AbbVie Inc has a 12-month low of $60.40 and a 12-month high of $125.86. The firm has a market capitalization of $180,520.00, a PE ratio of 27.45, a PEG ratio of 1.06 and a beta of 1.61. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.44 by $0.04. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The business had revenue of $7.74 billion during the quarter, compared to analyst estimates of $7.53 billion. During the same period in the previous year, the company posted $1.20 EPS. The firm’s revenue was up 13.9% compared to the same quarter last year. research analysts predict that AbbVie Inc will post 7.46 earnings per share for the current year.

WARNING: “AbbVie Inc (NYSE:ABBV) Shares Sold by NTV Asset Management LLC” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/15/abbvie-inc-abbv-stake-decreased-by-ntv-asset-management-llc-2.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply